Nautilus Biotechnology, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Nautilus Biotechnology, Inc. (NAUT) reported Net Income (Loss) Available to Common Stockholders, Basic of -$14.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-07-28
- Nautilus Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$14.47M.
- Nautilus Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$14.70M.
- Nautilus Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$13.78M.
- Nautilus Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$13.57M.
- Nautilus Biotechnology, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$59.00M.
- Nautilus Biotechnology, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$70.78M.
- Nautilus Biotechnology, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$63.67M.
- Nautilus Biotechnology, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$57.92M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.47M 10-Q · filed 2026-07-28 | -$29.17M 10-Q · filed 2026-07-28 | -$42.95M derived: sum of 3 quarters · filed 2026-07-28 | -$56.52M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | -$14.70M 10-Q · filed 2026-04-28 | -$28.48M derived: sum of 2 quarters · filed 2026-04-28 | -$42.05M derived: sum of 3 quarters · filed 2026-04-28 | -$57.09M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | -$13.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$27.36M derived: sum of 2 quarters · filed 2026-02-26 | -$42.39M derived: sum of 3 quarters · filed 2026-07-28 | -$59.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$13.57M 10-Q · filed 2025-10-28 | -$28.61M derived: sum of 2 quarters · filed 2026-07-28 | -$45.22M 10-Q · filed 2025-10-28 | -$62.81M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | -$15.03M 10-Q · filed 2026-07-28 | -$31.65M 10-Q · filed 2026-07-28 | -$49.24M derived: sum of 3 quarters · filed 2026-07-28 | -$65.69M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | -$16.61M 10-Q · filed 2026-04-28 | -$34.21M derived: sum of 2 quarters · filed 2026-04-28 | -$50.65M derived: sum of 3 quarters · filed 2026-04-28 | -$68.66M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$17.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$34.04M derived: sum of 2 quarters · filed 2026-02-26 | -$52.05M derived: sum of 3 quarters · filed 2026-02-26 | -$70.78M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$16.45M 10-Q · filed 2025-10-28 | -$34.46M derived: sum of 2 quarters · filed 2025-10-28 | -$53.19M 10-Q · filed 2025-10-28 | -$70.21M derived: sum of 4 quarters · filed 2025-10-28 |
| 2024-06-30 | -$18.01M 10-Q · filed 2025-07-31 | -$36.74M 10-Q · filed 2025-07-31 | -$53.76M derived: sum of 3 quarters · filed 2025-07-31 | -$69.64M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | -$18.73M 10-Q · filed 2025-04-29 | -$35.75M derived: sum of 2 quarters · filed 2025-04-29 | -$51.63M derived: sum of 3 quarters · filed 2025-04-29 | -$67.44M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | -$17.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$32.90M derived: sum of 2 quarters · filed 2025-02-27 | -$48.71M derived: sum of 3 quarters · filed 2025-02-27 | -$63.67M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$15.88M 10-Q · filed 2024-10-29 | -$31.69M derived: sum of 2 quarters · filed 2024-10-29 | -$46.65M 10-Q · filed 2024-10-29 | -$60.06M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | -$15.81M 10-Q · filed 2024-07-30 | -$30.77M 10-Q · filed 2024-07-30 | -$44.18M derived: sum of 3 quarters · filed 2024-07-30 | -$58.24M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | -$14.96M 10-Q · filed 2024-04-30 | -$28.37M derived: sum of 2 quarters · filed 2024-04-30 | -$42.44M derived: sum of 3 quarters · filed 2024-04-30 | -$57.13M derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-31 | -$13.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$27.47M derived: sum of 2 quarters · filed 2024-02-28 | -$42.16M derived: sum of 3 quarters · filed 2024-02-28 | -$57.92M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$14.06M 10-Q · filed 2023-10-31 | -$28.75M derived: sum of 2 quarters · filed 2023-10-31 | -$44.52M 10-Q · filed 2023-10-31 | -$61.20M derived: sum of 4 quarters · filed 2023-10-31 |
| 2022-06-30 | -$14.69M 10-Q · filed 2023-08-02 | -$30.45M 10-Q · filed 2023-08-02 | -$47.14M derived: sum of 3 quarters · filed 2023-08-02 | -$61.65M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | -$15.76M 10-Q · filed 2023-05-02 | -$32.45M derived: sum of 2 quarters · filed 2023-05-02 | -$46.96M derived: sum of 3 quarters · filed 2023-05-02 | -$57.67M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | -$16.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$31.19M derived: sum of 2 quarters · filed 2023-02-23 | -$41.91M derived: sum of 3 quarters · filed 2023-02-23 | -$50.31M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$14.50M 10-Q · filed 2022-11-01 | -$25.22M derived: sum of 2 quarters · filed 2022-11-01 | -$33.63M 10-Q · filed 2022-11-01 | -$38.98M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | -$10.71M 10-Q · filed 2022-08-02 | -$19.12M 10-Q · filed 2022-08-02 | -$24.47M derived: sum of 3 quarters · filed 2022-08-02 | -$28.45M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | -$8.41M 10-Q · filed 2022-05-03 | -$13.76M derived: sum of 2 quarters · filed 2022-05-03 | -$17.74M derived: sum of 3 quarters · filed 2022-05-03 | -$21.09M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | -$5.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$9.33M derived: sum of 2 quarters · filed 2022-02-24 | -$12.69M derived: sum of 3 quarters · filed 2022-02-24 | -$15.62M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$3.98M 10-Q · filed 2021-11-02 | -$7.33M derived: sum of 2 quarters · filed 2021-11-02 | -$10.27M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | -$3.35M 10-Q · filed 2021-08-10 | -$6.29M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |